Anifrolumab: the new frontier in the treatment of genetic interferonopathies.

IF 5.1 2区医学 Q1 RHEUMATOLOGY

RMD Open Pub Date : 2024-09-23 DOI:10.1136/rmdopen-2024-004780

Marie-Louise Frémond, Clémence David, Christophe Richez

引用次数: 0

查看原文本刊更多论文

Anifrolumab：治疗遗传性干扰素病的新领域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

RMD Open RHEUMATOLOGY-

CiteScore

7.30

自引率

6.50%

发文量

205

审稿时长

14 weeks

期刊介绍： RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.